ALA-BCC-CT008

• Research type

  Research Study

• Full title

  A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) in comparison to Metvix® in the treatment of non-aggressive basal cell carcinoma (BCC) with photodynamic therapy (PDT)

• IRAS ID

  145036

• Contact name

  Colin Morton

• Contact email

  colin.morton@nhs.net

• Sponsor organisation

  Biofrontera Bioscience GmbH

• Eudract number

  2013-003241-42

• REC name

  East of Scotland Research Ethics Service REC 2

• REC reference

  14/ES/0004

• Date of REC Opinion

  23 Jan 2014

• REC opinion

  Further Information Favourable Opinion